AN2728 Topical Ointment to Treat Mild-to-Moderate Plaque-Type Psoriasis

• Drug: AN2728 ointment, 2%
  
  AN2728 ointment, 2%, applied twice daily for 12 weeks
• Drug: Ointment Vehicle
  
  Ointment Vehicle, applied twice daily for 12 weeks

• Experimental: AN2728 ointment, 2%
  
  AN2728 ointment, 2%
  Intervention: Drug: AN2728 ointment, 2%
• Placebo Comparator: Ointment Vehicle
  
  Ointment Vehicle
  Intervention: Drug: Ointment Vehicle

Inclusion Criteria:

• Clinical diagnosis of stable mild-to-moderate plaque-type psoriasis involving 2-35% of total body surface area (BSA) excluding face, scalp, and genitals
• Willingness and ability to apply study medication as directed, comply with study instructions, and commit to attending all study visits
• Women of childbearing potential must agree to use contraception for the entire study period

Exclusion Criteria:

• Any dermatological conditions that could interfere with clinical evaluations
• Concurrent or recent use of certain topical or systemic medications without a sufficient washout period
• Significant confounding conditions as assessed by study doctor
• Participated in any other trial of an investigational drug within 30 days or participation in a research study concurrent with this study
• Use of lithium- or hydroxychloroquine-containing products (e.g., Plaquenil)
• Use of a beta-blocking medication (e.g., propranolol) if the dose has not been stabilized for at least 3 months
• Pregnancy or lactation